



Press Release

GRAFTYS achieves CE recertification and MDSAP certification for Australia, Brazil, Canada and USA

Jumet (Belgium) & Aix-en-Provence (France), October 6, 2020 – GRAFTYS SA ("Graftys"), a global leader in resorbable bone cements, is pleased to announce the CE recertification in Europe and the certification of its Quality Management System in conformity with the Medical Device Single Audit Program (MDSAP) in Australia, Brazil, Canada and the United States of America for the Design, Manufacture and Distribution of its Sterile Calcium Phosphate Resorbable Bone Void Fillers and related Delivery Systems.

"By achieving the MDSAP certification and the CE recertification of our bone cements, we continue our commitment to reach the highest Quality Assurance standards and to strictly comply with local laws and regulatory requirements in all jurisdictions we are operating in, including Europe, North and South America, for the benefits of our partners, our surgeons and most importantly our patients." commented Enrico Bastianelli, MD, MBA, Chief Executive Officer of Graftys.

Contact: Enrico Bastianelli at news@graftys.com

For background information: www.graftys.com

About Graftys

Graftys is an innovation-driven medtech company committed to the development and manufacturing of synthetic bone biomaterials. Graftys' products are registered in more than 30 countries worldwide, including Europe, the USA, Canada and South America. Graftys' mission is to become a major player in the design, manufacturing & distribution of bone biomaterials, thanks to a solid portfolio of products built on clinical evidence and addressing patient's/surgeon's medical needs, and thanks to an innovation-driven pipeline through partnerships with leading academic research institutions in Europe.